RESTON, Va., June 16, 2025 -- Perfusion Medical, an emerging biopharmaceutical company developing a pipeline of life-saving, acute cardiovascular therapies to transform intensive care medicine, today announced that it has received a scholarship from the Virginia Biotechnology Research Partnership Authority to participate in the BIO International Convention, June 16-19, 2025, in Boston, MA.
"We are grateful for the support from Virginia Bio, and we are glad to contribute to Virginia's life-science ecosystem with our technology, PM-208, which was discovered and developed at Virginia Commonwealth University," said Perfusion's Chief Executive Officer, Gerard Eldering. "We are excited to convene with industry leaders to discuss the progress of PM-208, which is designed to treat severe hypovolemic shock by increasing tissue perfusion and facilitating rapid transfer of oxygen into oxygen-starved tissues and organs."
During BIO International, Perfusion's Operations Lead, Liz Bloomfield, will conduct one-on-one meetings with registered investors and potential partners to discuss its lead candidate, PM-208, a novel IV therapeutic designed to rapidly re-establish blood flow through tissue capillaries, resolving ischemia and enhancing organ perfusion. PM-208 is designed to treat capillary compression due to ischemia – a major unsolved problem in hemorrhagic shock as well as other ischemic injuries, including acute kidney injury, cardiac bypass dysfunction, and ischemic reperfusion injury.
"Virginia Bio is proud to facilitate Perfusion Medical's invitation to this year's BIO International Convention, as the company provides a perfect example of the healthcare advances being developed in our state," said John Newby, Chief Executive Officer of Virginia Bio. "Virginia Bio works to foster a life sciences ecosystem and is recognized nationally for its innovation, commercial success, and contributions to improved health for all. Notably, Perfusion's potentially life-saving technology has received consistent support from the military, pointing to a major benefit to growing a life-science company in our state."
About Perfusion Medical
Perfusion Medical is an emerging biopharmaceutical company developing life-saving, acute cardiovascular therapies to transform critical care medicine, with a focus on shock and ischemic conditions. The company's lead candidate, PM-208, is designed to rapidly restore microvascular perfusion, resolving ischemia and protecting vital organs. Preclinical data suggest that PM-208 has the potential to improve survival outcomes, accelerate patient recovery, and reduce long-term comorbidities in conditions such as hemorrhagic shock, cardiogenic shock, and acute kidney injury. In addition to investor capital, Perfusion has secured funding and support from the Defense Health Agency (DHA), U.S. Air Force (AFWERX), and the National Institutes of Health (NIH). Perfusion Medical is headquartered in Reston, VA. For more information, please visit https://perfusionmedical.com.
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
